Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
ASPIRIN
1 other identifier
interventional
11,976
7 countries
14
Brief Summary
Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and geographically diverse population could best be accomplished by the established infrastructure of the Global Network for Women's and Children's Health Research (GN).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2016
Typical duration for not_applicable
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 30, 2015
CompletedFirst Posted
Study publicly available on registry
April 7, 2015
CompletedStudy Start
First participant enrolled
March 23, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 11, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 11, 2019
CompletedResults Posted
Study results publicly available
September 8, 2021
CompletedNovember 21, 2024
November 1, 2024
3.1 years
March 30, 2015
January 8, 2021
November 19, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of Preterm Birth
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous.
At delivery
Secondary Outcomes (3)
Incidence of Hypertensive Disorders of Pregnancy
Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Incidence of Small for Gestational Age (SGA)
At delivery or at Day 42 after delivery
Incidence of Perinatal Mortality
At delivery or at Day 42 after delivery
Other Outcomes (14)
Maternal Outcome 1 - Incidence of Vaginal Bleeding
At delivery or at Day 42 after delivery
Maternal Outcome 2 - Incidence of Antepartum Hemorrhage
At delivery or at Day 42 after delivery
Maternal Outcome 3 - Incidence of Postpartum Hemorrhage
At delivery or at Day 42 after delivery
- +11 more other outcomes
Study Arms (2)
Intervention Arm
ACTIVE COMPARATORWomen will be randomized equally to receive daily low dose aspirin (LDA) \[also known as acetylsalicylic acid (ASA)\] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
Placebo Arm
PLACEBO COMPARATORWomen will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
Interventions
Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
Eligibility Criteria
You may qualify if:
- Nulliparous women between 18 - 40 years of age. Minors who are ≥ 14 years of age may be enrolled if permitted by the country's ethical guidelines.
- No more than two previous first trimester pregnancy losses
- No medical contraindications to aspirin;
- Single live intrauterine pregnancy (IUP) between 6 0/7 and 13 6/7 weeks GA corroborated by an early dating ultrasound and with presence of a heartbeat.
You may not qualify if:
- Women prescribed daily aspirin for more than 7 days;
- Multiple gestations;
- Hemoglobin \< 7.0 gm/dl at screening;
- Any other medical conditions that may be considered a contraindication per the judgment of the site investigator (e.g., Lupus, Type 1 Diabetes, or any other known significant disease)
- Blood pressure ≥ 140/90 (Systolic blood pressure ≥ 140 and diastolic ≥ 90 at screening)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (14)
University of Alabama, Birmingham
Birmingham, Alabama, 35233, United States
University of Colorado, Denver
Denver, Colorado, 80045, United States
Indiana University
Indianapolis, Indiana, 46202, United States
Boston University
Boston, Massachusetts, 02215, United States
Columbia University
New York, New York, 10032, United States
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Kinshasa School of Public Health
Kinshasa, Democratic Republic of the Congo
Institute of Nutrition of Central America and Panama (INCAP)
Guatemala City, 01015, Guatemala
KLE University's Jawaharlal Nehru Medical College
Belagavi, Karnataka, India
Lata Medical Research Foundation
Nagpur, India
Moi University School of Medicine
Eldoret, 30100, Kenya
The Aga Khan University
Karachi, 74800, Pakistan
University Teaching Hospital
Lusaka, Zambia
Related Publications (66)
Abramovici A, Cantu J, Jenkins SM. Tocolytic therapy for acute preterm labor. Obstet Gynecol Clin North Am. 2012 Mar;39(1):77-87. doi: 10.1016/j.ogc.2011.12.003. Epub 2012 Jan 4.
PMID: 22370109BACKGROUNDAnanth CV, Joseph KS, Oyelese Y, Demissie K, Vintzileos AM. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gynecol. 2005 May;105(5 Pt 1):1084-91. doi: 10.1097/01.AOG.0000158124.96300.c7.
PMID: 15863548BACKGROUNDAnderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep. 2003 Nov 7;52(9):1-85.
PMID: 14626726BACKGROUNDBaschat AA, Guclu S, Kush ML, Gembruch U, Weiner CP, Harman CR. Venous Doppler in the prediction of acid-base status of growth-restricted fetuses with elevated placental blood flow resistance. Am J Obstet Gynecol. 2004 Jul;191(1):277-84. doi: 10.1016/j.ajog.2003.11.028.
PMID: 15295379BACKGROUNDBeck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, Rubens C, Menon R, Van Look PF. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ. 2010 Jan;88(1):31-8. doi: 10.2471/BLT.08.062554. Epub 2009 Sep 25.
PMID: 20428351BACKGROUNDBecker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006 Mar 22;295(12):1420-7. doi: 10.1001/jama.295.12.1420.
PMID: 16551714BACKGROUNDBower SJ, Harrington KF, Schuchter K, McGirr C, Campbell S. Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol. 1996 Jul;103(7):625-9. doi: 10.1111/j.1471-0528.1996.tb09829.x.
PMID: 8688387BACKGROUNDCAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 Jun 7;349(9066):1641-9.
PMID: 9186381BACKGROUNDChavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, Garcia-Paleta Y, Vital-Reyes VS, Reyes A. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol. 2003 Apr;188(4):986-92. doi: 10.1067/mob.2003.203.
PMID: 12712098BACKGROUNDChien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG. 2000 Feb;107(2):196-208. doi: 10.1111/j.1471-0528.2000.tb11690.x.
PMID: 10688503BACKGROUNDCLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994 Mar 12;343(8898):619-29.
PMID: 7906809BACKGROUNDACOG committee opinion no. 561: Nonmedically indicated early-term deliveries. Obstet Gynecol. 2013 Apr;121(4):911-915. doi: 10.1097/01.AOG.0000428649.57622.a7.
PMID: 23635710BACKGROUNDCoomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS. Individualising use of aspirin to prevent pre-eclampsia: a framework for clinical decision making. BJOG. 2003 Oct;110(10):882-8. No abstract available.
PMID: 14550356BACKGROUNDCoomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003 Jun;101(6):1319-32. doi: 10.1016/s0029-7844(03)00169-8.
PMID: 12798543BACKGROUNDDuley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2004;(1):CD004659. doi: 10.1002/14651858.CD004659.
PMID: 14974075BACKGROUNDDuley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659. doi: 10.1002/14651858.CD004659.pub2.
PMID: 17443552BACKGROUNDEbrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005 Oct;46(5):826-31.
PMID: 16158479BACKGROUNDErkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001 Jun;44(6):1466-7. doi: 10.1002/1529-0131(200106)44:63.0.CO;2-C. No abstract available.
PMID: 11407709BACKGROUNDFitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676-88. doi: 10.1172/jci110814.
PMID: 6338043BACKGROUNDGoffinet F, Aboulker D, Paris-Llado J, Bucourt M, Uzan M, Papiernik E, Breart G. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG. 2001 May;108(5):510-8. doi: 10.1111/j.1471-0528.2001.00116.x.
PMID: 11368138BACKGROUNDGoldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4.
PMID: 18177778BACKGROUNDGoldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med. 1998 Jul 30;339(5):313-20. doi: 10.1056/NEJM199807303390506. No abstract available.
PMID: 9682045BACKGROUNDHamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2012. Natl Vital Stat Rep. 2013 Sep;62(3):1-20.
PMID: 24321416BACKGROUNDHeyborne KD. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol. 2000 Sep;183(3):523-8. doi: 10.1067/mob.2000.106757.
PMID: 10992168BACKGROUNDKajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009 Apr;40(4):1176-80. doi: 10.1161/STROKEAHA.108.538025. Epub 2009 Mar 5.
PMID: 19265049BACKGROUNDKim YJ, Lee BE, Park HS, Kang JG, Kim JO, Ha EH. Risk factors for preterm birth in Korea: a multicenter prospective study. Gynecol Obstet Invest. 2005;60(4):206-12. doi: 10.1159/000087207. Epub 2005 Jul 26.
PMID: 16088197BACKGROUNDKnight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev. 2000;(2):CD000492. doi: 10.1002/14651858.CD000492.
PMID: 10796208BACKGROUNDKozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002 Dec;187(6):1623-30. doi: 10.1067/mob.2002.127376.
PMID: 12501074BACKGROUNDLandau D, Shelef I, Polacheck H, Marks K, Holcberg G. Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use. Am J Perinatol. 1999;16(9):441-4. doi: 10.1055/s-1999-6810.
PMID: 10774758BACKGROUNDLandolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19(3):617-33. doi: 10.1016/j.beha.2005.07.011.
PMID: 16781491BACKGROUNDLi DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003 Aug 16;327(7411):368. doi: 10.1136/bmj.327.7411.368.
PMID: 12919986BACKGROUNDLoe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol. 2005 Jul;106(1):173-9. doi: 10.1097/01.AOG.0000168622.56478.df.
PMID: 15994634BACKGROUNDLow-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Lancet. 1993 Feb 13;341(8842):396-400.
PMID: 8094168BACKGROUNDMarch of Dimes, Save the Children, WHO. (2012). Born Too Soon: The Global Action Report on Preterm Birth. (M. V. K. CP Howson JE Lawn., Ed.). Geneva: World Health Organization.
BACKGROUNDMarret S, Marchand L, Kaminski M, Larroque B, Arnaud C, Truffert P, Thirez G, Fresson J, Roze JC, Ancel PY; EPIPAGE Study Group. Prenatal low-dose aspirin and neurobehavioral outcomes of children born very preterm. Pediatrics. 2010 Jan;125(1):e29-34. doi: 10.1542/peds.2009-0994. Epub 2009 Dec 21.
PMID: 20026499BACKGROUNDMathews TJ, Menacker F, MacDorman MF; Centers for Disease Control and Prevention, National Center for Health Statistics. Infant mortality statistics from the 2002 period: linked birth/infant death data set. Natl Vital Stat Rep. 2004 Nov 24;53(10):1-29.
PMID: 15622996BACKGROUNDMcCormick MC, Richardson DK. Premature infants grow up. N Engl J Med. 2002 Jan 17;346(3):197-8. doi: 10.1056/NEJM200201173460310. No abstract available.
PMID: 11796855BACKGROUNDMorris JM, Fay RA, Ellwood DA, Cook CM, Devonald KJ. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol. 1996 Jan;87(1):74-8. doi: 10.1016/0029-7844(95)00340-1.
PMID: 8532271BACKGROUNDNewnham JP, Godfrey M, Walters BJ, Phillips J, Evans SF. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):370-4. doi: 10.1111/j.1479-828x.1995.tb02144.x.
PMID: 8717556BACKGROUNDNorgard B, Puho E, Czeizel AE, Skriver MV, Sorensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005 Mar;192(3):922-3. doi: 10.1016/j.ajog.2004.10.598.
PMID: 15746692BACKGROUNDNorton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993 Nov 25;329(22):1602-7. doi: 10.1056/NEJM199311253292202.
PMID: 8232428BACKGROUNDPapageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. BJOG. 2005 Jun;112(6):703-9. doi: 10.1111/j.1471-0528.2005.00519.x.
PMID: 15924523BACKGROUNDPatrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 Dec 1;353(22):2373-83. doi: 10.1056/NEJMra052717. No abstract available.
PMID: 16319386BACKGROUNDPeruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Lancet. 1999 Nov 6;354(9190):1615. doi: 10.1016/S0140-6736(99)03105-0.
PMID: 10560684BACKGROUNDPhysicians' health study: aspirin and primary prevention of coronary heart disease. N Engl J Med. 1989 Dec 28;321(26):1825-8. doi: 10.1056/NEJM198912283212610. No abstract available.
PMID: 2594041BACKGROUNDRE, B., & AS, B. (2006). Preterm Birth: Causes, Consequences, and Prevention. (I. of M. of the Academies, Ed.). Washington, DC: The National Academies Press.
BACKGROUNDRidker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352(13):1293-304. doi: 10.1056/NEJMoa050613. Epub 2005 Mar 7.
PMID: 15753114BACKGROUNDSaigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008 Jan 19;371(9608):261-9. doi: 10.1016/S0140-6736(08)60136-1.
PMID: 18207020BACKGROUNDSchisterman EF, Silver RM, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, Lynch AM, Perkins NJ, Mumford SL, Galai N. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet. 2014 Jul 5;384(9937):29-36. doi: 10.1016/S0140-6736(14)60157-4. Epub 2014 Apr 2.
PMID: 24702835BACKGROUNDSeamon LG, Cohn DE, Henretta MS, Kim KH, Carlson MJ, Phillips GS, Fowler JM. Minimally invasive comprehensive surgical staging for endometrial cancer: Robotics or laparoscopy? Gynecol Oncol. 2009 Apr;113(1):36-41. doi: 10.1016/j.ygyno.2008.12.005. Epub 2009 Jan 24.
PMID: 19168206BACKGROUNDSilver RM, Edwin SS, Trautman MS, Simmons DL, Branch DW, Dudley DJ, Mitchell MD. Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. J Clin Invest. 1995 Feb;95(2):725-31. doi: 10.1172/JCI117719.
PMID: 7860753BACKGROUNDSmith GC. Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol. 2001 Feb;184(3):489-96. doi: 10.1067/mob.2001.109735.
PMID: 11228508BACKGROUNDSmith GC, Shah I, Pell JP, Crossley JA, Dobbie R. Maternal obesity in early pregnancy and risk of spontaneous and elective preterm deliveries: a retrospective cohort study. Am J Public Health. 2007 Jan;97(1):157-62. doi: 10.2105/AJPH.2005.074294. Epub 2006 Nov 30.
PMID: 17138924BACKGROUNDSouter D, Harding J, McCowan L, O'Donnell C, McLeay E, Baxendale H. Antenatal indomethacin--adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol. 1998 Feb;38(1):11-6. doi: 10.1111/j.1479-828x.1998.tb02949.x.
PMID: 9521382BACKGROUNDSubtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, Uzan S, Quandalle F, Delcourt YM, Malek YM; Essai Regional Aspirine Mere-Enfant (ERASME) Collaborative Group. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 2). BJOG. 2003 May;110(5):485-91. doi: 10.1046/j.1471-0528.2003.t01-1-02097.x.
PMID: 12742333BACKGROUNDVainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG. 2002 Feb;109(2):161-7. doi: 10.1111/j.1471-0528.2002.01046.x.
PMID: 11888098BACKGROUNDVainio M, Riutta A, Koivisto AM, Maenpaa J. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand. 2004 Dec;83(12):1119-23. doi: 10.1111/j.0001-6349.2004.00396.x.
PMID: 15548142BACKGROUNDValero De Bernabe J, Soriano T, Albaladejo R, Juarranz M, Calle ME, Martinez D, Dominguez-Rojas V. Risk factors for low birth weight: a review. Eur J Obstet Gynecol Reprod Biol. 2004 Sep 10;116(1):3-15. doi: 10.1016/j.ejogrb.2004.03.007.
PMID: 15294360BACKGROUNDVan Marter LJ, Leviton A, Allred EN, Pagano M, Sullivan KF, Cohen A, Epstein MF. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996 May;97(5):658-63.
PMID: 8628603BACKGROUNDVane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8. doi: 10.1016/s0049-3848(03)00379-7.
PMID: 14592543BACKGROUNDVermillion ST, Robinson CJ. Antiprostaglandin drugs. Obstet Gynecol Clin North Am. 2005 Sep;32(3):501-17. doi: 10.1016/j.ogc.2005.04.006.
PMID: 16125046BACKGROUNDWerler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002 Jan 1;155(1):26-31. doi: 10.1093/aje/155.1.26.
PMID: 11772781BACKGROUNDYu Y, Cheng Y, Fan J, Chen XS, Klein-Szanto A, Fitzgerald GA, Funk CD. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest. 2005 Apr;115(4):986-95. doi: 10.1172/JCI23683. Epub 2005 Mar 17.
PMID: 15776109BACKGROUNDBucher S, Nowak K, Otieno K, Tenge C, Marete I, Rutto F, Kemboi M, Achieng E, Ekhaguere OA, Nyongesa P, Esamai FO, Liechty EA. Birth weight and gestational age distributions in a rural Kenyan population. BMC Pediatr. 2023 Mar 8;23(1):112. doi: 10.1186/s12887-023-03925-2.
PMID: 36890485DERIVEDHoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, Lokangaka A, Tshefu A, Bose CL, Mwapule A, Mwenechanya M, Chomba E, Carlo WA, Chicuy J, Figueroa L, Garces A, Krebs NF, Jessani S, Zehra F, Saleem S, Goldenberg RL, Kurhe K, Das P, Patel A, Hibberd PL, Achieng E, Nyongesa P, Esamai F, Liechty EA, Goco N, Hemingway-Foday J, Moore J, Nolen TL, McClure EM, Koso-Thomas M, Miodovnik M, Silver R, Derman RJ; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet. 2020 Jan 25;395(10220):285-293. doi: 10.1016/S0140-6736(19)32973-3.
PMID: 31982074DERIVEDHoffman MK, Goudar SS, Kodkany BS, Goco N, Koso-Thomas M, Miodovnik M, McClure EM, Wallace DD, Hemingway-Foday JJ, Tshefu A, Lokangaka A, Bose CL, Chomba E, Mwenechanya M, Carlo WA, Garces A, Krebs NF, Hambidge KM, Saleem S, Goldenberg RL, Patel A, Hibberd PL, Esamai F, Liechty EA, Silver R, Derman RJ. A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. BMC Pregnancy Childbirth. 2017 May 3;17(1):135. doi: 10.1186/s12884-017-1312-x.
PMID: 28468653DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Elizabeth McClure
- Organization
- RTI International
Study Officials
- STUDY DIRECTOR
Marion Koso-Thomas, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 30, 2015
First Posted
April 7, 2015
Study Start
March 23, 2016
Primary Completion
April 11, 2019
Study Completion
April 11, 2019
Last Updated
November 21, 2024
Results First Posted
September 8, 2021
Record last verified: 2024-11